R01 CA163793/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2013	1
2014	2
2015	3
2016	6
2017	3
2018	2
2019	3
2024	0

1

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Sharma P, et al. Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017. Cell. 2017. PMID: 28187290 Free PMC article. Review.

2

The future of immune checkpoint therapy.

Sharma P, Allison JP. Sharma P, et al. Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172. Science. 2015. PMID: 25838373 Review.

3

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Sharma P, Allison JP. Sharma P, et al. Cell. 2015 Apr 9;161(2):205-14. doi: 10.1016/j.cell.2015.03.030. Cell. 2015. PMID: 25860605 Free PMC article. Review.

4

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP. Wei SC, et al. Cell. 2017 Sep 7;170(6):1120-1133.e17. doi: 10.1016/j.cell.2017.07.024. Epub 2017 Aug 10. Cell. 2017. PMID: 28803728 Free PMC article.

5

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Gao J, et al. Cell. 2016 Oct 6;167(2):397-404.e9. doi: 10.1016/j.cell.2016.08.069. Epub 2016 Sep 22. Cell. 2016. PMID: 27667683 Free PMC article.

6

From the Guest Editor: Immune Checkpoint Therapy as a Weapon Against Cancer.

Sharma P. Sharma P. Cancer J. 2016 Mar-Apr;22(2):67. doi: 10.1097/PPO.0000000000000184. Cancer J. 2016. PMID: 27111899 Free PMC article. No abstract available.

7

Immune Checkpoint Therapy and the Search for Predictive Biomarkers.

Sharma P. Sharma P. Cancer J. 2016 Mar-Apr;22(2):68-72. doi: 10.1097/PPO.0000000000000185. Cancer J. 2016. PMID: 27111900 Free PMC article. Review.

8

Monitoring immune responses in the tumor microenvironment.

Wargo JA, Reddy SM, Reuben A, Sharma P. Wargo JA, et al. Curr Opin Immunol. 2016 Aug;41:23-31. doi: 10.1016/j.coi.2016.05.006. Epub 2016 May 27. Curr Opin Immunol. 2016. PMID: 27240055 Free PMC article. Review.

9

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.

Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P. Gao J, et al. Oncogene. 2015 Oct;34(43):5411-7. doi: 10.1038/onc.2015.5. Epub 2015 Feb 9. Oncogene. 2015. PMID: 25659583 Free PMC article. Review.

10

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.

Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Fan X, et al. J Exp Med. 2014 Apr 7;211(4):715-25. doi: 10.1084/jem.20130590. Epub 2014 Mar 31. J Exp Med. 2014. PMID: 24687957 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year